Starpharma has developed a pipeline of novel DEP® oncology products. Its clinical-stage assets, DEP® SN38, DEP® cabazitaxel, and DEP® docetaxel, are dendrimer-based chemotherapeutic drugs that have demonstrated improvements in efficacy and tolerability in Phase 2 clinical trials. Additionally, Starpharma has a preclinical pipeline of DEP® radiopharmaceuticals and DEP® Antibody-Drug Conjugates (ADCs) in development.
![DEP® Pipeline](/assets/uploads/2024-08/240627-dep-pipeline-for-website.png)
Partner with us
Contact our business development team to explore partnership opportunities with Starpharma.
Business Development
T: +61 3 8532 2700
E: busdev@starpharma.com